Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05838521 · ClinicalTrials.gov registry record · Phase 2

A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer

A Phase 2 study of Cervical Cancer, sponsored by Yale University.

Recruiting
Registry status
Phase 2
Development phase
20
Enrollment target
2
Study locations

NCT05838521 is a Phase 2 study of Cervical Cancer that is actively recruiting participants, run by Yale University. The registered enrollment target is 20 participants, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (96% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05838521, a Phase 2 study of Cervical Cancer, is actively recruiting participants, sponsored by Yale University.

RECRUITING
Registry status
Phase 2
Development phase
20 participants
Enrollment target
2
Study locations

Study Summary

This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.

Conditions Studied

Cervical Cancer

Interventions

  • DRUG Sacituzumab govitecan

Study Locations (2)

Connecticut

  • Smilow Cancer Hospital at Yale New Haven - New Haven

Ohio

  • Cleveland Clinic - Cleveland

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2023-06-02
Est. Completion 2028-06-01
Phase Phase 2

Sponsor

Yale University

1,492 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05838521

The ClinicalTrials.gov registry entry for NCT05838521 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 570-participant average among 144 other Cervical Cancer trials with a reported enrollment target (96% lower). The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Cervical Cancer appearing as the primary indexed condition, and to 1 intervention - of which Sacituzumab govitecan is the first listed.

NCT05838521 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Connecticut, Ohio.

Frequently Asked Questions

What is clinical trial NCT05838521 about?

NCT05838521 is a clinical study titled "A Study of Sacituzumab Govitecan (IMMU-132) in Patients With Recurrent or Persistent Cervical Cancer". This is a non-randomized Phase 2 study of sacituzumab govitecan (IMMU-132) in subjects with recurrent or persistent cervical cancer.

What is the current status of trial NCT05838521?

This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2023-06-02. Estimated completion is 2028-06-01.

What conditions does trial NCT05838521 study?

This clinical trial studies the following conditions: Cervical Cancer.

What interventions are being tested in trial NCT05838521?

The interventions under investigation include: Sacituzumab govitecan (DRUG).

Who is sponsoring clinical trial NCT05838521?

This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05838521 being conducted?

This trial has 2 study locations across Connecticut, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Cervical Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Cervical Cancer

All registered trials for this condition

Connecticut

All trials with a study site in Connecticut

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.